Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dual CD19-CD22 CAR T cells in advanced lymphoid malignancies
NCT04029038Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2019
- Primary completion
- Nov 2022
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous CD19/CD22 chimeric antigen receptor T-cells in B cell acute lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Optimal chimeric antigen receptor (CAR) T cell dose level at 30 days, Incidence of adverse events at 30 days and 1 more. Planned start May 2019; status: withdrawn.
02
Drugs
autologous CD19/CD22 chimeric antigen receptor T-cells
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)chronic lymphocytic leukemia (CLL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT04029038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04029038.